Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6AXV9)

Drug Name

TOL-101 Drug Info

Synonyms

MAb (transplant rejection), Tolera Therapeutics; Monoclonal antibody (transplant rejection), Tolera Therapeutics; Anti-TCR alpha/beta antibody (transplant rejection/type 1 diabetes/multiple sclerosis), Tolera

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DM6AXV9

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell receptor (TCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[3]
RGI-2001	DM4AC2F	Graft-versus-host disease	4B24	Phase 2	[4]
IR502	DMW2IF9	Plaque psoriasis	EA90.0	Phase 2	[5]
SAR444200	DM7J5H0	Aggressive cancer	2A00-2F9Z	Phase 2	[6]
MAGE-A10 TCR	DM6H3YS	Bladder cancer	2C94	Phase 1/2	[3]
NY-ESO-TCR	DMS0L6J	Melanoma	2C30	Phase 1/2	[3]
AFP TCR	DMHBUMZ	Hepatocellular carcinoma	2C12.02	Phase 1	[3]
BPX-701	DMYERSD	Acute myeloid leukaemia	2A60	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell receptor (TCR)	TT7AKW1	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01154387) Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection. U.S. National Institutes of Health.
2	First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
5	WO patent application no. 2004,0677,06, Production of multimeric proteins.
6	Clinical pipeline report, company report or official report of Sanofi